JP2012516897A5 - - Google Patents

Download PDF

Info

Publication number
JP2012516897A5
JP2012516897A5 JP2011549261A JP2011549261A JP2012516897A5 JP 2012516897 A5 JP2012516897 A5 JP 2012516897A5 JP 2011549261 A JP2011549261 A JP 2011549261A JP 2011549261 A JP2011549261 A JP 2011549261A JP 2012516897 A5 JP2012516897 A5 JP 2012516897A5
Authority
JP
Japan
Prior art keywords
seq
pharmaceutical composition
antibiotic
composition according
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011549261A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012516897A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/023214 external-priority patent/WO2010091189A1/en
Publication of JP2012516897A publication Critical patent/JP2012516897A/ja
Publication of JP2012516897A5 publication Critical patent/JP2012516897A5/ja
Pending legal-status Critical Current

Links

JP2011549261A 2009-02-04 2010-02-04 シュードモナス・エルギノーサ(PseudomonasAeruginosa)感染の治療のための抗生物質と抗体療法との組み合わせ Pending JP2012516897A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14995709P 2009-02-04 2009-02-04
US61/149,957 2009-02-04
PCT/US2010/023214 WO2010091189A1 (en) 2009-02-04 2010-02-04 Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection

Publications (2)

Publication Number Publication Date
JP2012516897A JP2012516897A (ja) 2012-07-26
JP2012516897A5 true JP2012516897A5 (https=) 2013-03-21

Family

ID=42133763

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011549261A Pending JP2012516897A (ja) 2009-02-04 2010-02-04 シュードモナス・エルギノーサ(PseudomonasAeruginosa)感染の治療のための抗生物質と抗体療法との組み合わせ

Country Status (5)

Country Link
US (1) US20100272736A1 (https=)
EP (1) EP2393515A1 (https=)
JP (1) JP2012516897A (https=)
CA (1) CA2751433A1 (https=)
WO (1) WO2010091189A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2784033A1 (en) 2009-12-22 2011-07-21 Kalobios Pharmaceuticals, Inc. A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection
BR112013031485B1 (pt) 2011-06-10 2022-06-14 Medimmune, Llc Anticorpo monoclonal isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, usos e método in vitro para bloqueio ou prevenção da ligação de p. aeruginosa a células epiteliais
BR112014011028B1 (pt) * 2011-11-07 2021-03-02 Medimmune, Llc anticorpo biespecífico, composição, e, uso da composição
CN118620074A (zh) * 2020-06-01 2024-09-10 北京三诺佳邑生物技术有限责任公司 特异性识别假单胞菌pcrv的抗体及其用途
FR3114970B1 (fr) * 2020-10-08 2023-06-30 Univ Tours Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires
WO2024261584A1 (en) * 2023-06-17 2024-12-26 Abgenics Lifesciences Private Limited A composition effective against beta-lactam antibiotic-resistant pseudomonas aeruginosa

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HU205630B (en) * 1985-06-06 1992-05-28 Genetic Systems Corp Process for producing monoclonal antibodys inhibiting exotoxine and toxic effect of pseudomonas aeruginosa and specific for them, celle lines producing them and pharmaceutical compositions
NZ218499A (en) * 1985-12-10 1990-04-26 Genetic Systems Corp Monoclonal antibodies against pseudomonas aeruginosa, pharmaceutical compositions and detection methods
DK172840B1 (da) * 1986-07-03 1999-08-09 Genetic Systems Corp Monoklonale antistoffer mod Pseudomonas aeruginosa flagella, farmaceutiske præparater indeholdende sådanne antistoffer og c
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
DE69930166T2 (de) 1998-11-25 2006-12-14 MCW Research Foundation, Inc., Milwaukee Verfahren und zusammensetzungen für impfung mit dem pseudomonas aeruginosa v-antigen
DK1353688T3 (da) * 2001-01-26 2007-04-10 Mcw Res Found Inc Fremgangsmåde og sammensætninger til immunisering med Psedomonas V-antigenet
JP4782700B2 (ja) 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
US20060134098A1 (en) 2004-11-16 2006-06-22 Kalobios, Inc. Immunoglobulin variable region cassette exchange
US8211648B2 (en) 2005-07-22 2012-07-03 Kalobios Pharmaceuticals, Inc. Secretion of antibodies without signal peptides from bacteria
US7846895B2 (en) * 2006-09-06 2010-12-07 The Regents Of The University Of California Selectively targeted antimicrobial peptides and the use thereof
EP2220117A2 (en) * 2007-11-30 2010-08-25 Kalobios Pharmaceuticals, Inc. Antibodies to the pcrv antigen of pseudomonas aeruginosa

Similar Documents

Publication Publication Date Title
Sanya et al. Recent advances in therapeutic targets identification and development of treatment strategies towards Pseudomonas aeruginosa infections
Ali et al. Phase 1 study of MEDI3902, an investigational anti–Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults
Reig et al. What is new in the anti–Pseudomonas aeruginosa clinical development pipeline since the 2017 WHO alert?
Falagas et al. Tetracyclines for multidrug-resistant Acinetobacter baumannii infections
ES2983252T3 (es) Tratamiento de las infecciones polibacterianas
Rhodes et al. Resistance trends and treatment options in gram-negative ventilator-associated pneumonia
JP2012516897A5 (https=)
JP2017519768A5 (https=)
JP2013515079A5 (https=)
JP2021063090A5 (https=)
JP2017512193A5 (https=)
JP2006522830A5 (https=)
JP2016507470A5 (https=)
US20220041695A1 (en) Method for preventing or treating nosocomial pneumonia
Wróblewska Novel therapies of multidrug-resistant Pseudomonas aeruginosa and Acinetobacter spp. infections: the state of the art
CN111372603A (zh) 针对铜绿假单胞菌感染的组合物和方法
Loos et al. 674. Pre-Clinical and Phase I Safety Data for Anti-Pseudomonas aeruginosa Human Monoclonal Antibody AR-105
Dunn Diagnosis and treatment of infection
Okumura et al. Infective endocarditis caused by highly penicillin-resistant Streptococcus pneumoniae: successful treatment with cefuzonam, ampicillin and imipenem
Tur Clinical Microbiology and Infectious Diseases (ECCMID)-28th European Congress. Madrid, Spain-April 21-24, 2018
JP7811652B2 (ja) リボース及びアミノ酸を含む医薬組成物
US20140120191A1 (en) Method of treating a disorder associated with sequestered bacteria
Odland IDWeek 2019
Odland IDWeek 2019. Washington, DC, USA-October 2-6, 2019
Kokai-Kun et al. 1337. SYN-004 (Ribaxamase) Protects the Gut Microbiome of Patients Treated With Ceftriaxone From Disruption and Reduces the Emergence of Antimicrobial Resistance